Compare Newegg Commerce Inc (NEGG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newegg Commerce Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Newegg Commerce Inc trades at $18.42 (market cap $398.29M), while Regeneron Pharmaceuticals Inc trades at $793.07 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 206× Newegg Commerce Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.
| NEGG | REGN | |
|---|---|---|
Market Cap | $398.29M | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $128.09 | $812.27 |
52-Week Low | $12.87 | $555.51 |
Enterprise Value | $397.09M | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newegg Commerce (NEGG) trades at $18.38, up 8.76% in the last session, with a bullish technical outlook and recent earnings beats. The company reported revenue of $1.44 billion for 2025, with a net loss narrowing to $4.88 million, showing improved profitability trends. Recent news highlights AI shopping features and exclusive product launches, indicating innovation efforts.
The outlook is cautiously optimistic due to earnings improvement and positive analyst sentiment, but risks include volatile cash flows, high P/E ratio, and competitive pressures in e-commerce. Institutional interest remains limited, with one analyst rating the stock a Buy as of 2026-08-12.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
